For years, Eli Lilly has been generating solid growth numbers -- but lately, they've been accelerating rapidly. The company is coming off a solid quarter where its revenue rose by 45% for the last ...

Shares of Eli Lilly & Co. LLY slid 3.00% to $844.27 Friday, on what proved to be an all-around grim trading session for the ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on UnitedHealth (UNH – Research Report) and Eli Lilly & Co (LLY – Research Report) with bullish ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative. The stock is reasonably valued given the growth opportunities in front ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other large cap dividend growth stocks. Investors continue to favor large-cap stocks ...

Eli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the stock market and healthcare system. Shares have performed well in 2025 ...

Eli Lilly and Company (NYSE: LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn's disease receiving ...

LLY PE Ratio (Forward) data by YCharts. Given the popularity of GLP-1 drugs and the potential for an oral GLP-1 drug launch in 2026, Lilly remains very well positioned. As such, I think the stock ...

Lone Pine’s four new buys during the fourth quarter included, by size of position, Eli Lilly (LLY), Capital One (COF), Flutter (FLUT), and Cipher Mining (CIFR). Lone Pine exited three positions ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...